532987-11-4

Upstream product

• 67-56-1 methanol 
• 7292-71-9 2-(3-chlorophenyl)glycine 
• 587-04-2 m-Chlorobenzaldehyde 

Downstream Products

• 532986-41-7 N-[1-(3-chlorophenyl)-2-hydroxyethyl]octanamide 
• 1227294-02-1 (2S,3S,3aS,9bS)-3-ethyl-2-methyl-2-(3-chlorophenyl)-1,2,3,3a,4,9b-hexahydrochromeno[4,3-b]pyrrole-2,3-dicarboxylate 
• 1322877-79-1 trimethyl (2S,3S,4R,5S)-2-(3-chlorophenyl)-5-(4-nitrophenyl)pyrrolidine-2,3,4-tricarboxylate 
• 25871-69-6 1,3,5-tribenzoylbenzene 
• 1423136-82-6 methyl 4-benzoyl-2-(3-chlorophenyl)-5-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxylate 
• 1423136-83-7 methyl 4-benzoyl-2-(3-chlorophenyl)-5-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxylate 
• 7292-71-9 2-(3-chlorophenyl)glycine 

Relevant academic research and scientific papers

Synthesis of Unprotected 2-Arylglycines by Transamination of Arylglyoxylic Acids with 2-(2-Chlorophenyl)glycine

The transamination of α-keto acids with 2-phenylglycine is an effective methodology for directly synthesizing unprotected α-amino acids. However, the synthesis of 2-arylglycines by transamination is problematic because the corresponding products, 2-arylglycines, transaminate the starting arylglyoxylic acids. Herein, we demonstrate the use of commercially available l-2-(2-chlorophenyl)glycine as the nitrogen source in the transamination of arylglyoxylic acids, producing the corresponding 2-arylglycines without interference from the undesired self-transamination process.

PLATELET ADP RECEPTOR INHIBITORS

Compounds are provided which are useful as platelet ADP receptor inhibitors, for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF

Compounds of formula (I) and salts and solvates thereof are provided: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.